The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Eugene Braunwald - One of the best experts on this subject based on the ideXlab platform.

Francesco Rubino - One of the best experts on this subject based on the ideXlab platform.

  • bariatric surgery an idf statement for obese type 2 diabetes
    Diabetic Medicine, 2011
    Co-Authors: John Dixon, Paul Zimmet, K G M M Alberti, Francesco Rubino
    Abstract:

    The International Diabetes Federation Taskforce on Epidemiology and Prevention of Diabetes convened a consensus working group of Diabetologists, endocrinologists, surgeons and public health experts to review the appropriate role of surgery and other gastrointestinal interventions in the treatment and prevention of Type 2 diabetes. The specific goals were: to develop practical recommendations for clinicians on patient selection; to identify barriers to surgical access and suggest interventions for health policy changes that ensure equitable access to surgery when indicated; and to identify priorities for research. Bariatric surgery can significantly improve glycaemic control in severely obese patients with Type 2 diabetes. It is an effective, safe and cost-effective therapy for obese Type 2 diabetes. Surgery can be considered an appropriate treatment for people with Type 2 diabetes and obesity not achieving recommended treatment targets with medical therapies, especially in the presence of other major co-morbidities. The procedures must be performed within accepted guidelines and require appropriate multidisciplinary assessment for the procedure, comprehensive patient education and ongoing care, as well as safe and standardized surgical procedures. National guidelines for bariatric surgery need to be developed for people with Type 2 diabetes and a BMI of 35 kg/m2 or more.

Eoin Obrien - One of the best experts on this subject based on the ideXlab platform.

  • cardiovascular risk assessment in low resource settings a consensus document of the european society of hypertension working group on hypertension and cardiovascular risk in low resource settings
    Journal of Hypertension, 2014
    Co-Authors: Pietro Amedeo Modesti, Piergiuseppe Agostoni, Charles Agyemang, Sanjay Basu, Athanase Benetos, Francesco P Cappuccio, Antonio Ceriello, Stefano Del Prato, Robert Kalyesubula, Eoin Obrien
    Abstract:

    The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 confirms ischemic heart disease and stroke as the leading cause of death and that hypertension is the main associated risk factor worldwide. How best to respond to the rising prevalence of hypertension in resource-deprived settings is a topic of ongoing public-health debate and discussion. In low-income and middle-income countries, socioeconomic inequality and cultural factors play a role both in the development of risk factors and in the access to care. In Europe, cultural barriers and poor communication between health systems and migrants may limit migrants from receiving appropriate prevention, diagnosis, and treatment. To use more efficiently resources available and to make treatment cost-effective at the patient level, cardiovascular risk approach is now recommended. In 2011, The European Society of Hypertension established a Working Group on 'Hypertension and Cardiovascular risk in low resource settings', which brought together cardiologists, Diabetologists, nephrologists, clinical trialists, epidemiologists, economists, and other stakeholders to review current strategies for cardiovascular risk assessment in population studies in low-income and middle-income countries, their limitations, possible improvements, and future interests in screening programs. This report summarizes current evidence and presents highlights of unmet needs.

Kamran Mahmood Ahmed Aziz - One of the best experts on this subject based on the ideXlab platform.

  • management of type 1 and type 2 diabetes by insulin injections in diabetology clinics a scientific research review
    Recent Patents on Endocrine Metabolic & Immune Drug Discovery, 2012
    Co-Authors: Kamran Mahmood Ahmed Aziz
    Abstract:

    Better control of the diabetic metabolic state will prevent the diabetes complications. However in current clinical practice, it is sometimes difficult to achieve this goal. Additionally, physicians find themselves in an equivocal position to initiate insulin therapy, its selection, combining with Oral agents and further management. The current article was written to focus on diabetes pathogenesis at molecular level, its classification and management by insulin injections. Knowledge of basic biochemistry, pharmacology with kinetics of Insulin is essential for diabetes management. Nonetheless, it should be a priority to search for evidence based clinical methodologies for selecting the patients for initiating, modifying or combining the insulin therapy. Type-1 diabetic patients are best controlled on basal bolus insulin regimens. However in type-2 diabetes, metformin with lifestyle modifications should be the first line therapy, thereafter combined with oral hypoglycemic agents or shifting to insulin gradually if diabetes remains uncontrolled. Metformin is recommended to be prescribed with insulin as compared to oral hypoglycemic agents which should be discontinued while starting insulin. Monitoring the insulin therapy on regular visits to Diabetologist and diabetes multidisciplinary team remains the integral part of diabetes management. The review also outlines relevant and recent insulin analogue patents for the management of Diabetes.

Cristina Hernandez - One of the best experts on this subject based on the ideXlab platform.

  • cognitive impairment and dementia a new emerging complication of type 2 diabetes the Diabetologist s perspective
    Acta Diabetologica, 2017
    Co-Authors: Rafael Simo, Andreea Ciudin, Olga Simoservat, Cristina Hernandez
    Abstract:

    Type 2 diabetes mellitus (T2D) and Alzheimer's disease (AD) are two of the most common diseases of aging around the world. Given the frequency with which T2D and AD occur, the notion that people with T2D may be at increased risk for AD has large societal consequences, and understanding the mechanistic links between these diseases is imperative for the development of effective AD prevention and treatment strategies. Apart from being an accelerator of AD, T2D is associated with a progressive cognitive decline. Impaired insulin signaling, inflammation, the accumulation of advanced glycation end-products and oxidative stress all play an essential role in the pathogenesis of both AD and diabetic complications. Therefore, it is reasonable to postulate that these pathways are involved in the increased risk of dementia that occurs in the T2D population. The early diagnosis of cognitive impairment and the identification of the subset of patients at a higher risk of developing AD is a challenge for healthcare providers, and meeting it will permit us to implement a personalized medicine, which is an essential issue in diabetes care with significant therapeutic implications. The main gaps that should be filled to achieve this objective are examined.